The FDA approved a premarket approval supplement for the CGuard Prime TransCarotid Stent System, InspireMD said on November 12. The approval adds transcarotid artery revascularization to the label and brings an 80 cm delivery system to market. Labeling requires the stent to be used with an embolic protection system named in the instructions for use.

CGUARDIANS II supported the submission. The single-arm study enrolled 50 patients at high surgical risk across 11 US sites and paired the stent with the ENROUTE Transcarotid Neuroprotection System. At 30 days InspireMD reported 100 percent acute device success, no deaths, strokes, myocardial infarctions or stent thrombosis, and complete stent patency in evaluable patients. The implant is a self-expanding nitinol stent covered by the company's MicroNet micromesh.

InspireMD puts US TCAR volume above 35,000 procedures a year, inside a carotid stenting market it sizes at roughly 75,000, and says the approval about doubles the addressable market for the platform. The company announced a proposed public offering the same afternoon with Lake Street Capital Markets as sole book runner. A supplement with 50 patients behind it is a cheap way to add a procedure to an approved implant, and the question for vascular surgeons is whether 30-day numbers at that sample size are enough to move them off a stent they already use.